Drug repurposing, using an existing approved drug for a new indication, looks attractive on paper. It promises to skip years of early development and reduce costs. But the path is rarely as clean as it sounds.
In this webinar, Kevin Grimes draws on his career spanning internal medicine, industry, and academic drug discovery to give an honest account of where repurposing works, where it breaks down, and what researchers and entrepreneurs need to understand before betting on it.
Kevin is a Professor of Chemical & Systems Biology and Co-Director of the SPARK program at Stanford University. He holds an M.D. from Brown University and an MBA from Stanford, and spent fifteen years working across medical devices, life science consulting, and biotechnology before returning to Stanford to lead SPARK. He teaches drug discovery, drug development, and the economics of biotechnology, and continues to practice internal medicine.
In this webinar, you will hear about:
- What makes drug repurposing genuinely attractive, and where that logic tends to fall apart
- The scientific, regulatory, and commercial challenges specific to repurposing strategies
- Real examples from Kevin's experience at the crossroads of medicine, business, and research
This webinar is hosted by SPARK-BIH as part of the SPARK Europe Education Webinar Series, running every month on a Wednesday at 16:00 CET.
Please enter "SPARK-Bordeaux" for the question Which SPARK site are you associated with?